MIMEDX GROUP, INC.

(MDXG)
  Report
Real-time Estimate Cboe BZX  -  05/23 03:10:17 pm EDT
3.510 USD   -2.50%
09:15aMiMedx Group, Inc. - Leading Independent Proxy Advisory Firm Glass Lewis Recommends That MIMEDX Shareholders Vote 'FOR ALL' Of The Company's Proposals
AQ
05/20MiMedx Says Glass Lewis Recommends in Favor of Director Nominees, Say-on-Pay Proposal
MT
05/20Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company's Proposals
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference

12/22/2021 | 08:00am EDT

MARIETTA, Ga., Dec. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present during the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12 at 5:15 PM EST. Institutional investors interested in a virtual meeting with management during the conference may reach out to their J.P. Morgan representative.

Investors and other interested parties may access the live webcast on the Events page of the Investors section of the Company’s website or by clicking here. A replay of the webcast will be available for 30 days on the Company’s website at www.mimedx.com following the conclusion of the presentation.

About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact:
Jack Howarth
Investor Relations
404-360-5681
jhowarth@mimedx.com

Contact:
Hilary Dixon
Corporate & Strategic Communications
404-323-4779
hdixon@mimedx.com


Primary Logo

Source: MiMedx Group, Inc

2021 GlobeNewswire, Inc., source Press Releases

All news about MIMEDX GROUP, INC.
09:15aMiMedx Group, Inc. - Leading Independent Proxy Advisory Firm Glass Lewis Recommends Tha..
AQ
05/20MiMedx Says Glass Lewis Recommends in Favor of Director Nominees, Say-on-Pay Proposal
MT
05/20Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders..
AQ
05/20Glass Lewis & Co Supports MiMedx Group Inc Nominees and Proposals
CI
05/18MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
AQ
05/18MiMedx Group Files an Investor Presentation to Shareholders
CI
05/18Prescience Point Capital Management Calls on MiMedx to Confirm the Company Has Received..
PR
05/18Prescience Point Capital Management Provides Information to the Shareholders
CI
05/16MIMEDX Mails Letter to Shareholders
AQ
05/16MiMedx Group Inc Mails Letter to Shareholders
CI
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2022 273 M - -
Net income 2022 -30,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -16,9x
Yield 2022 -
Capitalization 405 M 405 M -
Capi. / Sales 2022 1,48x
Capi. / Sales 2023 1,30x
Nbr of Employees 811
Free-Float 97,9%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,60 $
Average target price 14,17 $
Spread / Average Target 294%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Scott M. Turner Vice President-Procurement
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-40.40%405
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
MODERNA, INC.-46.35%54 195
WUXI APPTEC CO., LTD.-17.77%42 735